Alle patientbrochurer bør indeholde følgende elementer: • At lenalidomid er teratogent hos dyr og forventes at have teratogen virkning hos mennesker • At Revlimid kan forårsage neutropeni og trombocytopeni og at regelmæssige blodtest er nødvendige • Beskrivelse af patientkortet og dets nødvendighed • Bortskaffelse af uønsket medicin • Nationale eller andre specifikke foranstaltninger, der finder anvendelse, for at en recept på Revlimid, kan blive udleveret • At patienten ikke må give Revlimid til andre personer • At patienten ikke må donere blod • At patienten skal oplyse lægen om enhver bivirkning
All patient brochures should contain the following elements: • That lenalidomide is teratogenic in animals and is expected to be teratogenic in humans • That Revlimid may cause neutropenia and thrombocytopenia and the need for regular blood tests • Description of the patient card and its necessity • Disposal of unwanted medicine • National or other applicable specific arrangements for a prescription for Revlimid to be dispensed • That the patient should not give Revlimid to any other person • That the patient should not donate blood • That the patient should tell their doctor about any adverse events